Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,648 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases/Diagnoses Clear all
Completed Not applicable Interventional

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

NCT04632849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GEM + CGM
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
35 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

NCT00656448
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions
Procrit
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 1, 2026, 11:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnostic Evaluation of the Tear Film

NCT00761917
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Tear Film Analyzer
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
8
States / cities
Fayetteville, Arkansas • Morrow, Georgia • Oak Lawn, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

NCT01994889
View directory record Official record
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions
Tafamidis, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

NCT03426891
View directory record Official record
Conditions
Glioblastoma, Brain Tumor, GBM
Interventions
Pembrolizumab, Vorinostat, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

NCT02306291
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
GMI-1271, Mitoxantrone, Etoposide, Cytarabine, Idarubicin
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 1 Interventional

Topical Naloxone to Diagnose Ocular Pain

NCT04454281
View directory record Official record
Conditions
Dry Eye Syndromes, Neuropathic Pain
Interventions
Naloxone Hydrochloride 0.4 MG/ML
Drug
Lead sponsor
Seema Capoor
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Early Phase 1 Interventional

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

NCT02490930
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma
Interventions
Fingolimod
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 1, 2026, 11:35 AM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

NCT03560960
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 1, 2026, 11:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

NCT00829959
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 1, 2026, 11:35 AM EDT
Completed No phase listed Observational

Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients

NCT01560169
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
La Jolla, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 1, 2026, 11:35 AM EDT
Not listed No phase listed Observational

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study

NCT03951324
View directory record Official record
Conditions
Biliary Stricture, Pancreas Cancer, Cholangiocarcinoma, Bile Duct Cancer, Bile Duct Neoplasms Malignant, Bile Duct Neoplasms, Bile Duct Lesions, Bile Duct Obstruction, Bile Duct Diseases, Bile Duct Obstruction, Extrahepatic, Bile Duct Stenosi, Bile Duct Adenoma, Pancreatic Duct Stricture, Pancreatic Duct Stenosis, Pancreatic Duct Obstruction, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis
Interventions
Interobserver agreement or Interrater agreement
Other
Lead sponsor
Innovative Digestive Health Education and Research Inc
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 1, 2026, 11:35 AM EDT
Completed No phase listed Observational

Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging

NCT01434043
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Disease, Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 1, 2026, 11:35 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Lenalidomide
Drug
Lead sponsor
European Myeloma Network B.V.
Network
Eligibility
18 Years and older
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
42
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 1, 2026, 11:35 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans

NCT01662297
View directory record Official record
Conditions
Insomnia, Mental Health Disorder, Substance Use Disorder
Interventions
Quetiapine, Trazodone
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 1, 2026, 11:35 AM EDT
Terminated Not applicable Interventional

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

NCT04474613
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Liquid biopsy
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 1, 2026, 11:35 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

NCT03223103
View directory record Official record
Conditions
Glioblastoma
Interventions
Poly-ICLC, Tumor Treating Fields, Peptides
Drug · Device · Biological
Lead sponsor
Adilia Hormigo
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 1, 2026, 11:35 AM EDT
Completed No phase listed Observational Results available

A Multi-Center Trial of the ProLung Test™

NCT01566682
View directory record Official record
Conditions
Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions
Not listed
Lead sponsor
Fresh Medical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

NCT01410227
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor (rVWF), Placebo, Recombinant factor VIIII (rFVIII)
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Sacramento, California • Miami, Florida • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 1, 2026, 11:35 AM EDT
Not listed Phase 2 Interventional

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

NCT00660283
View directory record Official record
Conditions
Glioma
Interventions
Temozolomide
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 3 Interventional Results available

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

NCT02159469
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 1, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00720356
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, erlotinib hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 1, 2026, 11:35 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 11:35 AM EDT